29-kDa: A Potential Candidate for Anti-Tick Vaccine Antigen Source as Immunogenic and Stage Reactive Targeting Hard-Bodied Hyalomma Ticks Ixodidae

Abstract

The objective of present study is to develop a vaccine against Hyalomma hard-bodied tick and to analyze relevant experimental data on immunized indigenous horse breed Morna. Montanide (ISA-50) adjuvant-based vaccine induced significantly (pandlt;0.02) higher antibody titre through intradermal route with 99.98% vaccine efficacy. Humoral response was determined though indirect ELISA; where peak level of serum antibody was recorded after six weeks interval of post-immunization. Most of hematology and biochemical parameters remained consistent to normal reference values. Our report also indicates a significant percentage decline in the numbers of engorged ticks, eggs mass, eggs number and increased tick rejection. The animal travel history can promote tick burden and is a potential risk factor. Based on biological and hematological parameters, it is possible to conclude that 29-kDa antigen can be used as an effective antigen vaccine candidate to control tick infestation detected through humoral response.